Recordati SpA (MIL:REC) Quality Rank


MIL:REC Recordati SpA MIL:REC
94 GF Score
Price €51.35
GF Value €60.74
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Recordati SpA Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Recordati SpA Quality Rank Related Terms

MIL:REC
94GF Score
Recordati SpA MIL:REC
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Recordati SpA (MIL:REC) Overvalued in 2026?

Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued. The current stock price of €51.35 is trading 15.5% below its estimated GF Value™ of €60.74. GuruFocus considers Recordati SpA to be Modestly Undervalued.

Key valuation signals for MIL:REC:

  • Quality Rank:
  • GF Value™: €60.74 vs. price of €51.35 (15.5% below fair value)
  • GF Score™: 94/100 with 3 warning signs

No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Recordati SpA Business Description

Address Via Matteo Civitali 1, MIlan, ITA, 20148
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
94GF Score

Get the complete analysis for MIL:REC

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€51.35
Price
€60.74
GF Value